See, Play and Learn
Macular degeneration, or age-related macular degeneration (AMD), is a leading cause of vision loss in Americans 60 and older. It is a disease that destroys your sharp, central vision. You need central vision to see objects clearly and to do tasks such as reading and driving.
AMD affects the macula, the part of the eye that allows you to see fine detail. It does not hurt, but it causes cells in the macula to die. There are two types: wet and dry. Wet AMD happens when abnormal blood vessels grow under the macula. These new blood vessels often leak blood and fluid. Wet AMD damages the macula quickly. Blurred vision is a common early symptom. Dry AMD happens when the light-sensitive cells in the macula slowly break down. Your gradually lose your central vision. A common early symptom is that straight lines appear crooked.
Regular comprehensive eye exams can detect macular degeneration before the disease causes vision loss. Treatment can slow vision loss. It does not restore vision.
NIH: National Eye Institute
Diagnosis and Tests
- Dilating Eye Drops (American Association for Pediatric Ophthalmology and Strabismus)
Treatments and Therapies
- Age-Related Eye Disease Studies (AREDS/AREDS2) (National Eye Institute)
- Choosing Wisely When It Comes to Eye Care: Antibiotics for Eye Injections (American Academy of Ophthalmology)
- Age-related macular degeneration: MedlinePlus Genetics (National Library of Medicine)
- Stargardt macular degeneration: MedlinePlus Genetics (National Library of Medicine)
Statistics and Research
- Blood Pressure Drugs and AMD (American Academy of Ophthalmology)
- NIH Study Provides Clarity on Supplements for Protection Against Blinding Eye Disease (National Eye Institute)
- ClinicalTrials.gov: Macular Degeneration (National Institutes of Health)
Journal Articles References and abstracts from MEDLINE/PubMed (National Library of Medicine)
- Article: Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment...
- Article: Electrophysiological evaluation and 18-month follow-up of two regimens with aflibercept for...
- Article: Survival of an HLA-mismatched, bioengineered RPE implant in dry age-related macular...
- Macular Degeneration -- see more articles
- How the Eyes Work (National Eye Institute)